💉FDA PHARMA TODAY
May 7, 2018
European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation
Application for Opdivo Plus Yervoy Combination for Treatment of
First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC)
http://www.ono.co.jp/eng/news/pdf/sm_cn180507_2.pdf
May 7, 2018
Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study
Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma
http://www.ono.co.jp/eng/news/pdf/sm_cn180507_1.pdf